Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2016 - 2018)

Vanda Pharmaceuticals' Gains from Sales and Divestitures history spans 8 years, with the latest figure at $475367.0 for Q1 2018.

  • For Q1 2018, Gains from Sales and Divestitures rose 36.79% year-over-year to $475367.0; the TTM value through Mar 2018 reached $475367.0, up 36.79%, while the annual FY2017 figure was $362313.0, 25.95% up from the prior year.
  • Gains from Sales and Divestitures for Q1 2018 was $475367.0 at Vanda Pharmaceuticals, up from $362313.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $475367.0 in Q1 2018 and bottomed at $209562.0 in Q1 2014.
  • The 5-year median for Gains from Sales and Divestitures is $287666.0 (2016), against an average of $287189.8.
  • The largest YoY upside for Gains from Sales and Divestitures was 37.48% in 2014 against a maximum downside of 4.16% in 2014.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $209562.0 in 2014, then rose by 10.27% to $231093.0 in 2015, then increased by 24.48% to $287666.0 in 2016, then increased by 25.95% to $362313.0 in 2017, then surged by 31.2% to $475367.0 in 2018.
  • Per Business Quant, the three most recent readings for VNDA's Gains from Sales and Divestitures are $475367.0 (Q1 2018), $362313.0 (Q4 2017), and $356127.0 (Q3 2017).